Eye mounted device for therapeutic agent release
US-12167978-B2 · Dec 17, 2024 · US
US2016206743A1 · US · A1
| Field | Value |
|---|---|
| Publication number | US-2016206743-A1 |
| Application number | US-201514918115-A |
| Country | US |
| Kind code | A1 |
| Filing date | Oct 20, 2015 |
| Priority date | Jun 15, 2012 |
| Publication date | Jul 21, 2016 |
| Grant date | — |
A practical reading order for non-experts. Skip the full description unless you need deep technical detail.
What the patent document calls the invention.
A short plain-language summary of the technical disclosure.
Who owns or filed the patent and who is credited as inventor.
Filing, priority, publication, and grant dates set the timeline.
The legal scope of protection — read this for what is actually claimed.
Technology tags used to group this patent with similar filings.
Prior art links and similar publications in this corpus.
Official abstract text for this publication.
Disclosed herein are glycidol-based polymers, nanoparticles, and methods related thereto useful for drug delivery. This abstract is intended as a scanning tool for purposes of searching in the particular art and is not intended to be limiting of the present invention.
Opening claim text (preview).
What is claimed is: 1 . A polymer comprising repeating units selected from: wherein R 0 is selected from H, alkyl, NH 2 , and R 1 ; wherein R 1 comprises a crosslinking functionality; wherein repeating units A1, A2, B1, and B2 account for at least about 50 wgt % of the polymer; and wherein the ratio of (A1+A2):(B1+B2) is greater than 1. 2 . The polymer of claim 1 , further comprising at least one repeating unit formed from a monomer selected from: or a combination thereof. 3 . The polymer of claim 2 , wherein the polymer comprises at least one repeating unit from a monomer selected from: or a combination thereof, and wherein the polymer is oxidized to form repeating units comprising epoxides or alkynes. 4 . The polymer of claim 1 , further comprising crosslinks, wherein the crosslinks comprises wherein at least one of is not 0. 5 . The polymer of claim 4 , wherein the crosslinks comprises one or more of or any combination thereof. 6 . The polymer of claim 4 , wherein the polymer comprises 7 . A nanoparticle comprising the polymer of claim 1 . 8 . The nanoparticles of claim 7 , wherein the polymer is crosslinked via crosslinks, wherein the crosslinks comprises wherein at least one of is not 0. 9 . A method for making a polymer, the method comprising the step of polymerizing glycidol in the presence of a tin catalyst. 10 . The method of claim 9 , wherein the tin catalyst is Sn(OTf) 2 . 11 . The method of claim 9 , wherein the resultant polymer comprises repeating units selected from: wherein R 0 is selected from H, alkyl, NH 2 , and R 1 ; wherein R 1 comprises a crosslinking functionality; wherein repeating units A1, A2, B1, and B2 account for at least about 50 wgt % of the polymer; and wherein the ratio of (A1+A2):(B1+B2) is greater than 1. 12 . The method of claim 9 , wherein the resultant polymer further comprises at least one repeating unit formed from a monomer selected from: or a combination thereof. 13 . The method of claim 9 , further comprising the step of crosslinking the polymer with crosslinks, wherein the wherein the crosslinks comprises wherein at least one of is not 0. 14 . The method of claim 9 , wherein the polymerization step is performed at a temperature of from −80° C. to 50° C. 16 . A method of forming a nanoparticle comprising: (a) providing a polymer of claim 3 ; and (b) crosslinking the polymer with crosslinks, wherein the crosslinks comprises wherein at least one of is not 0, thereby forming a nanoparticle. 17 . A drug delivery method comprising the step of administering to a subject a composition comprising the polymer of claim 1 or the nanoparticle of claim 7 , in combination with at least one pharmaceutically active agent and/or biologically active agent. 18 . A pharmaceutical composition comprising (a) the compound of claim 1 or a nanoparticle of claim 7 ; (b) pharmaceutically active agent and/or biologically active agent; and (c) a pharmaceutically acceptable carrier. 19 . A composition comprising (a) a polymer comprising repeating units formed from monomers wherein the polymer is crosslinked via crosslinks, wherein the crosslinks comprises wherein at least one of is not 0; and (b) a polymer of claim 1 , wherein the polymer of claim 1 is optionally covalently bonded to the polymer. 20 . A polymer comprising a structure formed from reacting a polymer of claim 1 further comprising repeating units with a polymer comprising at least one repeating unit formed from
obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, poly(lactide-co-glycolide) · CPC title
Macromolecular compounds obtained by reactions forming an ether link in the main chain of the macromolecule · CPC title
the other compounds containing carboxylic acid, ester or anhydride groups · CPC title
from unsaturated compounds (unsaturated oxiranes C08G65/14) · CPC title
aromatic · CPC title
Related publications grouped by family.
Answers are generated from the same data shown on this page.